627 / 1119
INTERTECC Preliminary Data: Jan 2015
All
(N=61)
Treated within 60 days, n (%)
57 (93%)
Completed 5 cycles cisplatin, n (%)
50 (82%)
Achieved Hard Bowel Constraint (V45<250cc), n (%)
55 (90%)
Achieved Soft Bowel Constraint (V45<200cc), n (%)
45 (74%)
Achieved Bone Marrow Constraints (V10<90%, V20<75%), n (%)
57 (93%)
Active Bone Marrow Sparing, n (%)
30 (43%)
FDG-PET, n (%)
15 (21%)
FLT-PET, n (%)
15 (21%)
Bowel V45 (cc) (mean, s.d.)
147 ± 89
Bone Marrow V10 (mean, s.d.)
84% ± 6.3%
Bone Marrow V20 (mean, s.d.)
65% ± 9.8%
Bone Marrow V30 (mean, s.d.)
42% ± 6.8%
Bone Marrow V40 (mean, s.d.)
19% ± 5.4%
Bone Marrow Mean Dose (Gy) (mean, s.d.)
26.0 ± 2.3
Active Bone Marrow Mean Dose (Gy) (mean, s.d.)
26.0 ± 2.6
Completed both baseline & Follow-up QOL Assessment, n (%)
54 (89%)
Courtesy: Loren Mell UCSD; PI INTERTECC